Pear Therapeutics (PEAR) Gets a Hold From BTIG
Pear Extends Selloff as Downgrades Follow Strategic Shake-up
Pear Therapeutics (PEAR) Was Downgraded to a Hold Rating at BTIG
Credit Suisse Maintains Outperform on Pear Therapeutics, Lowers Price Target to $7
Chardan Trims Price Target on Pear Therapeutics to $8 From $9 on Headcount Reduction, Reiterates Buy Rating
Pear Therapeutics (PEAR) Receives a Buy From BTIG
BTIG Reaffirms Their Buy Rating on Pear Therapeutics (PEAR)
Analysts Are Bullish on These Healthcare Stocks: Viridian Therapeutics (VRDN), Pear Therapeutics (PEAR)
Pear Therapeutics Is Maintained at Buy by BTIG
Pear Therapeutics Price Target Cut to $5.00/Share From $11.00 by BTIG
BTIG Maintains Buy on Pear Therapeutics, Lowers Price Target to $5
Pear Therapeutics Is Maintained at Buy by Chardan Capital
Chardan Capital Maintains Buy on Pear Therapeutics, Lowers Price Target to $9
Chardan Capital Keeps Their Buy Rating on Pear Therapeutics (PEAR)
BTIG Sticks to Its Buy Rating for Pear Therapeutics (PEAR)
Pear Therapeutics Price Target Cut to $9.00/Share From $11.00 by Credit Suisse
Pear Therapeutics Is Maintained at Outperform by Credit Suisse
Credit Suisse Lowers Pear Therapeutics' Price Target to $9 from $11, Adjusts Guidance While Awaiting Reorganization Impact; Keeps Outperform Rating
Credit Suisse Maintains Outperform on Pear Therapeutics, Lowers Price Target to $9
BTIG Adjusts Pear Therapeutics' Price Target to $11 from $12, Keeps Buy Rating
No Data